Liquid Biopsy Market
If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].
Liquid biopsy is a plasma or fluid-based alternative to invasive tissue biopsies and is considered one of fastest growing in vitro diagnostics markets in the world today. The global market for liquid biopsy assays and services totaled nearly $2.5bn in 2022 and is projected to grow at an extremely robust double-digit rate over the next 5 years.
The liquid biopsy market has attracted hundreds of innovative biotech/IVD companies in a race to commercialize single-cancer and multi-cancer/multigene liquid biopsy panel tests using next-generation sequencing (NGS) technology. NGS liquid biopsy assays provide crucial information about a patient’s cancer using various circulating molecular biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, proteins, and others. Additionally, the assays can detect ctDNA in blood specimens and evaluate exons from hundreds of genes and report cancer-associated point mutations, insertion/deletions (indels), copy number amplifications, and fusions/rearrangements. Machine-learning algorithms and advanced bioinformatics are deployed to single out clinically relevant biomarkers.
Increasingly, liquid biopsy is being viewed as a valuable tool in the early screening, diagnosis, monitoring, and targeted treatment of cancer due to its ability to detect cancer-related biomarkers or mutations using a single blood draw (compared to invasive tissue biopsy). Since approximately 50% of cancers are diagnosed at an advanced stage, early detection may substantially improve patient survivability. Liquid biopsy also can supplement traditional tissue biopsies or help patients avoid unnecessary surgery (eg in prostate cancer). Using liquid biopsy, companion diagnostics (CDx) can be developed to detect biomarkers and better identify patients who may respond best to cancer therapies – with the overall goal of improving targeted therapies, clinical outcomes, and extending lives.
This report includes a discussion of products, revenues, forecast markets, competitors, and opportunities in the global market for liquid biopsy tests/services. Revenues include sales derived from: liquid biopsy test kits/reagents/library prep and other materials used in the testing of blood-based oncology biomarkers from soluble analytes [eg cell-free DNA (cfDNA)/ctDNA, cell-free RNA (cfRNA), CTCs, exosomes, methylation]; and Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory services and analysis or send-out laboratory services in which a sample is sent to a centralized testing location. Geographical regions covered include North America, Europe, Asia-Pacific, and the Rest of World, and the forecast range is 2022–27.
Related Medtech Insight articles:
- News We’re Watching: Illumina Looks At Grail Options, New AdvaMed Digital Health Division, Evolut FX Gets CE Mark
- Companies Find Growth Opportunities In Maturing Colorectal Cancer Blood-Based Screening Market
- Minute Insight: Guardant And Illumina Resolve Litigation, Agree To Partnership
- Subscribe to Medtech Insight to view these articles and more!